<h2 class="show-for A05">Indication</h2>
<p class="show-for A05">KENGREAL<sup>&reg;</sup> (cangrelor) for Injection is a P2Y<sub>12</sub> platelet inhibitor indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y<sub>12</sub> platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.</p>
<h2>Important Safety Information</h2>
<ul data-isi-list class="isi-list">
	<li class="A05 A10 A15 A20 A40 A45 A55 A70 A75 A80 A95">
		<p>KENGREAL<sup>&reg;</sup> (cangrelor) for Injection is contraindicated in patients with significant active bleeding.</p>
		<p>KENGREAL<sup>&reg;</sup> is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to cangrelor or any component of the product.</p>
	</li>
	<li class="A25 A30 A35 A50 A60 A65 A85 A90">
		<p>Drugs that inhibit platelet P2Y<sub>12</sub> function, including KENGREAL<sup>&reg;</sup>, increase the risk of bleeding. In CHAMPION PHOENIX, bleeding events of all severities were more common with KENGREAL<sup>&reg;</sup> than with clopidogrel. Bleeding complications with KENGREAL<sup>&reg;</sup> were consistent across a variety of clinically important subgroups. Once KENGREAL<sup>&reg;</sup> is discontinued, there is no antiplatelet effect after an hour.</p>
	</li>
	<li class="A05 A10 A15 A20 A40 A45 A55 A70 A75 A80 A95">
		<p>The most common adverse reaction is bleeding.</p>
	</li>
</ul>
<p class="isi-link" data-isi-link><b class="grape">Please see full <a href="#isi" data-href="A100">Important Safety Information</a><span class="hide-for-aside"> and full <a href="#pi" data-pi>Prescribing Information</a></span>.</b></p>